"Weakness is Buying Opportunity, Clinical Programs Remain Underappreciated by Investors" - Arcutis Biotherapeutics (ARQT) Defended at Mizuho Securities, Buy Rating and $57 Price Target Reiterated
Tweet Send to a Friend
Mizuho Securities analyst Uy Ear reiterated a Buy rating and $57.00 price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
